EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder

Wan Miao, Jinlin Guo iD, Huifang Cheng iD, Qianqian Zhao

Infection and Drug Resistance · 2023-09 · Volume 16 · 6277-6284

DOI: 10.2147/idr.s429706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection and Drug Resistance, 2023-09. Verfasst von Wan Miao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, People's Republic of China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Cefoperazone/sulbactam is a β-lactam/β-lactamase inhibitor combination effective against intra-abdominal, urinary tract, and respiratory infections. Although some studies have suggested that cefoperazone/sulbactam is associated with coagulation disorders, it remains debatable whether the combination of cefoperazone/sulbactam with tigecycline or valproic acid increases the risk of bleeding, as both drugs can lead to coagulation disorders. This study aimed to explore the risk factors of cefoperazone/sulbactam-induced coagulopathy. Patients and Methods: This was a single-center, retrospective, nested case-control study. The sample groups were derived from individuals registered at the Department of Neurosurgery, Shanxi Provincial People's Hospital. Propensity score matching (PSM) was used to adjust for demographic data. Conditional logistic regression was used to estimate the matched odds ratios representing the odds of cefoperazone/sulbactam-induced coagulopathy (CIC), and a receiver operating characteristic curve was used to determine the optimal cut-off conditions.

Results

After PSM, 155 and 56 patients were included in the control and case groups, respectively. Multivariate analysis revealed that advanced age, treatment duration, and total dose were independent risk factors of cefoperazone/sulbactam-induced coagulation disorders. Concomitant use of vitamin K was an independent protective factor against CIC. The optimal cut-off for the length of treatment was 5 d, and the cut-off for the total dose was 48 g.

Conclusion

Tigecycline and valproic acid were not associated with CIC. Advanced age and long treatment duration are risk factors for CIC. Supplementation with vitamin K during cefoperazone/sulbactam treatment was associated with a reduced risk.

Schlagwörter

Stichwörter der Autor:innen

cefoperazone/sulbactamcoagulopathytigecyclinevalproic acid

Autor:innen und Institutionen

  • Department of Pharmacy, Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, People's Republic of China.

ORCID-Profile: Jinlin Guo, Huifang Cheng

Zitieren

APA

Miao, W., Guo, J., Cheng, H., & Zhao, Q. (2023). Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder. Infection and Drug Resistance, Volume 16, 6277-6284. https://doi.org/10.2147/idr.s429706

Vancouver

Miao W, Guo J, Cheng H, Zhao Q. Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder. Infection and Drug Resistance. 2023;Volume 16:6277-6284. doi:10.2147/idr.s429706

BibTeX
@article{Miao2023,
  author = {Miao, Wan and Guo, Jinlin and Cheng, Huifang and Zhao, Qianqian},
  title = {Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder},
  journal = {Infection and Drug Resistance},
  year = {2023},
  volume = {Volume 16},
  pages = {6277--6284},
  doi = {10.2147/idr.s429706}
}
Kostenlos starten →